Conference
Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs)
Authors
Pond GR; Siu LL; Moore MJ; Oza AM; Hirte H; Winquist E; Goss G; Hudes G; Degendorfer P; Townsley CA
Volume
25
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
June 20, 2007
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
18
ISSN
0732-183X